Biochemical and clinical evidence for uremic toxicity

被引:31
作者
Bouré, T [1 ]
Vanholder, R [1 ]
机构
[1] Ghent Univ Hosp, Dept Internal Med, Div Nephrol, B-9000 Ghent, Belgium
关键词
dialysis; middle molecules; protein bound solutes; urea; uremic syndrome; uremic toxins;
D O I
10.1111/j.1525-1594.2004.47315.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The uremic syndrome is a mix of clinical features resulting from multiple organ dysfunctions which develop when kidney failure progresses, and is attributed to the retention of solutes, which under normal conditions are excreted by the healthy kidneys into the urine. The most practical classification of uremic solutes is based on their physicochemical characteristics that influence their dialytic removal, in (1) small water soluble compounds, (2) the larger "middle molecules," and (3) the protein bound compounds. Hence, uremic retention is much more complex than originally believed. Among the small water soluble compounds, urea exerts not much toxic activity and is not very representative in its kinetic behavior for many other uremic solutes. Among the middle molecules, many have been recognized to exert biological activity and hence to contribute to the uremic syndrome. Specific dialysis strategies apply large pore membranes to remove those middle molecules and have a beneficial impact on uremic morbidity and mortality. A substantial number of uremic solutes are protein bound. Only recently, a relation between their concentration and clinical status could be demonstrated. Likewise, it was only recently possible to demonstrate more than standard removal with super-flux dialysis membranes. To further improve characterization of uremic solutes and to develop directed therapeutic approaches, further concerted action among various groups of researchers will be needed.
引用
收藏
页码:248 / 253
页数:6
相关论文
共 61 条
[1]  
Abreo K, 1997, J AM SOC NEPHROL, V8, P935
[2]   THE MIDDLE MOLECULE HYPOTHESIS IN PERSPECTIVE [J].
BABB, AL ;
AHMAD, S ;
BERGSTROM, J ;
SCRIBNER, BH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1981, 1 (01) :46-50
[3]   In vitro effect of advanced glycation end-products on human polymorphonuclear superoxide production [J].
Bernheim, J ;
Rashid, G ;
Gavrieli, R ;
Korzets, Z ;
Wolach, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2001, 31 (12) :1064-1069
[4]   Sudden and cardiac death rates in hemodialysis patients [J].
Bleyer, AJ ;
Russell, GB ;
Satko, SG .
KIDNEY INTERNATIONAL, 1999, 55 (04) :1553-1559
[5]   Relationship of dialysis membrane and cause-specific mortality [J].
Bloembergen, WE ;
Hakim, RM ;
Stannard, DC ;
Held, PJ ;
Wolfe, RA ;
Agodoa, LYC ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (01) :1-10
[6]   Relationship of dose of hemodialysis and cause-specific mortality [J].
Bloembergen, WE ;
Stannard, DC ;
Port, FK ;
Wolfe, RA ;
Pugh, JA ;
Jones, CA ;
Greer, JW ;
Golper, TA ;
Held, PJ .
KIDNEY INTERNATIONAL, 1996, 50 (02) :557-565
[7]   HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[8]  
CHANDRAN PKG, 1993, J AM SOC NEPHROL, V4, P1199
[9]  
Churchill DN, 1995, NEPHROL DIAL TRANSPL, V10, P52
[10]   Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins [J].
D'Hooge, R ;
Van de Vijver, G ;
Van Bogaert, PP ;
Marescau, B ;
Vanholder, R ;
De Deyn, PP .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1764-1775